TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01783925

Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.
Study: NCT06526130

Intervention type: PROCEDURE
Intervention: General anaesthesia
Description: Intravenous or volatile general anesthesia was preformed with different type of airway management (endotracheal tube, laryngeal mask and bag mask ventilation)

Intervention type: PROCEDURE
Intervention: Neuraxial anaesthesia
Description: spinal or epidural injections of local anesthetic with or without opioid
Study: NCT02235428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Study: NCT00722111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lingual press
Description: lingual press (high-intensity, oral, non-swallowing)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: effortful swallowing
Description: effortful swallowing (high-intensity swallowing)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: natural swallowing
Description: natural swallowing (high frequency, low intensity swallowing)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: non-oral sham (control) exercise
Description: non-oral sham (control) exercise
Study: NCT04384341

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Bone densitometry (BMD)
Description: Recruitment of haemophilic patients during a routine visit at the haemophilia centre.~Information of the subjects that the study requires a BMD measure for all and a blood sampling for patients only.~After inclusion and exclusion criteria have been checked, the subject can sign the consent.~For all subjects, an appointment will be made for BMD measure.~For patients and controls: BMD will be measured by Dual Energy X-ray Absorptiometry (DXA) technology, on femoral and lumbar spine (L2-L4) sites.~Recruitment of healthy volunteers through registers (Clinical Investigation Centers) and advertisements.

Intervention type: RADIATION
Group type: OTHER
Intervention: Bone densitometry (BMD)
Description: Recruitment of haemophilic patients during a routine visit at the haemophilia centre.~Information of the subjects that the study requires a BMD measure for all and a blood sampling for patients only.~After inclusion and exclusion criteria have been checked, the subject can sign the consent.~For all subjects, an appointment will be made for BMD measure.~For patients and controls: BMD will be measured by Dual Energy X-ray Absorptiometry (DXA) technology, on femoral and lumbar spine (L2-L4) sites.~Recruitment of healthy volunteers through registers (Clinical Investigation Centers) and advertisements.
Study: NCT02515136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus-response
Description: See summary
Study: NCT04384341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling for patients only
Description: For patients, fVIII/fIX activity and antigen, thrombin generation potential and plasmatic markers of bone remodelling will be measured centrally.
Study: NCT03958981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Castor Oil
Description: The intervention group will be given 60 mL of castor oil in 140 mL of orange juice

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the control group will be given a sunflower oil as a placebo with a similar texture to castor oil
Study: NCT00636428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: oral midazolam, was prepared into a final solution (2.5 mg/mL) from injectable midazolam hydrochloride and a orange flavored syrup. For preparation, midazolam injection (5 mg/mL) was diluted 1:1 with the flavored syrup.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: oral midazolam, was prepared into a final solution (2.5 mg/mL) from injectable midazolam hydrochloride and a orange flavored syrup. For preparation, midazolam injection (5 mg/mL) was diluted 1:1 with the flavored syrup.
Study: NCT02588131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab plus MEDI4736
Description: tremelimumab1 mg/kg i.v over 60 minutes plus MEDI 4736 20 mg/kg i.v every four weeks for 4 doses, then MEDI4736 20 mg/kg IV every four weeks for additional 9 doses.
Study: NCT00037973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ventilation feedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ventilation feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Study: NCT02450409

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of TKA using the gap technique
Description: Implantation of total knee arthroplasty using a specific operative technique (GT) serving as control.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of TKA using anatomical alignment
Description: Implantation of total knee arthroplasty using a specific operative technique (AA) being experimental.
Study: NCT02834065

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary bypass machine
Description: Routinely used cardiopulmonary bypass machine (standard of care) will be used to initiate circulatory arrest

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary bypass machine
Description: Routinely used cardiopulmonary bypass machine (standard of care) will be used to initiate circulatory arrest

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary bypass machine
Description: Routinely used cardiopulmonary bypass machine (standard of care) will be used to initiate circulatory arrest
Study: NCT02746458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: Brief and intermittent blood flow restriction via a Delfi PTSII Tourniquet System will be used during physical therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delfi PTSII Tourniquet System
Study: NCT02331030

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supraclavicular
Description: Ultrasound-guided supraclavicular brachial plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular
Description: Ultrasound-guided supraclavicular brachial plexus block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pecs II block
Description: Ultrasound guided interfascial plane block between pectoralis minor and serratus anterior

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham block (Grade 1)
Description: Sham block -- with skin preparation, ultrasound scanning of pecs II block area, but no actual needle injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% 20ml
Description: Local anaesthetic solution administered for supraclavicular block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% 20ml
Description: Local anaesthetic solution administered for supraclavicular block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% 10ml
Description: Local anaesthetic solution administered for pecs II block
Study: NCT03937973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social rejection
Description: Social rejection paradigm

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social rejection
Description: Social rejection paradigm
Study: NCT01422720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine Acetate
Description: ESL tablets (800 mg) QD
Study: NCT02832076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcutaneous negative suction drain for 10 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No subcutaneous drain
Study: NCT02087228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genesys HydroTherm Ablator
Description: Heated water is circulated inside the uterus to destroy the lining of the uterus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency energy ablation device
Study: NCT00108901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Description: Vigorous intermittent physical activity in group format conducted in research gymnasium after school by research staff. Heart rate monitors documented each child's average heart rate on a daily basis. Small incentives were offered for achieving goal of \>150 bpm average HR each day and attending at least 80% of sessions (4 days/week).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Description: Vigorous intermittent physical activity in group format conducted in research gymnasium after school by research staff. Heart rate monitors documented each child's average heart rate on a daily basis. Small incentives were offered for achieving goal of \>150 bpm average HR each day and attending at least 80% of sessions (4 days/week).
Study: NCT04516694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive (gain)
Description: Participants will receive a daily financial incentive framed as a gain with money allocated each day of adherence to a self-care coal. Participants will receive an additional weekly incentive for meeting a clinical outcome goal.
Study: NCT02075593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets
Description: The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
Study: NCT02289391

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anesthesia induction
Description: -Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia induction
Description: -Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
Study: NCT00850993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannsoporfin
Description: Stannsoporfin administered as a single IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannsoporfin
Description: Stannsoporfin administered as a single IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannsoporfin
Description: Stannsoporfin administered as a single IM injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sterile saline solution) administered as a single IM injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PhotoTherapy (as needed)
Description: PT standard care administered as needed, based on bilirubin levels throughout the treatment period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PhotoTherapy (as needed)
Description: PT standard care administered as needed, based on bilirubin levels throughout the treatment period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PhotoTherapy (as needed)
Description: PT standard care administered as needed, based on bilirubin levels throughout the treatment period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PhotoTherapy (as needed)
Description: PT standard care administered as needed, based on bilirubin levels throughout the treatment period
Study: NCT00730496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterine cavity injection of day 2 embryo culture supernatant
Description: On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. But in the control group, this intervention was not done. Conventional ET was performed on the third day of embryo culture for both groups.
Study: NCT02222532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetronine
Description: Oral T3 was given 1 microgram/kgBW q6h since induction of anesthesia for 11 doses (for 60 hours)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was sacharum lactis, given q6h since induction of anesthesia for 11 doses (for 60 hours)
Study: NCT05423015

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota
Description: Probiotic product were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 15 mL of sterile water were added to the probiotic product.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota plus inulin
Description: The Syn-inulin products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of inulin (BENEO GmbH) were diluted in 15 mL of sterile water and added to Syn-inulin products.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota plus fructans from A. salmiana
Description: The Syn-A. salmiana products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of fructans from A. salmiana were diluted in 15 mL of sterile water and added to Syn-A.salmiana products.
Study: NCT01596634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bovine lactoferrin
Description: Given PO
Study: NCT04623671

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAP-1002
Description: 100-mL (total volume) infusion of 150M CDCs in 5% Human Serum Albumin (HSA)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution
Study: NCT00927316

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: E. coli 83972
Description: Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).~Placebo arm: Identical procedure but with saline, 30 ml.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: E. coli 83972
Description: Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).~Placebo arm: Identical procedure but with saline, 30 ml.
Study: NCT04516694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive (loss)
Description: Participants will receive a daily financial incentive framed as a loss with money allocated up front and taken away each day of non-adherence to a self-care coal. An additional weekly incentive will be deducted for failure to meet a clinical outcome goal.
Study: NCT04703530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hot footbath
Description: The experimental group was given a hot footbath with a temperature of 41℃±1℃ for 20 minutes at about 1-2 hours before sleep
Study: NCT04128696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: feladilimab
Description: feladilimab is available as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is available as an intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab is available as an intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo is available as an intravenous infusion.
Study: NCT01571635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTATERCEPT (ACE-011)
Description: 0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTATERCEPT (ACE-011)
Description: 0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTATERCEPT (ACE-011)
Description: 0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTATERCEPT (ACE-011)
Description: 0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTATERCEPT (ACE-011)
Description: 0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTATERCEPT (ACE-011)
Description: 0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.
Study: NCT01935531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% diclofenac in 2.5% hyaluronic acid gel
Study: NCT02096029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) Sampling
Description: 2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ask, Advise, Refer (physician brief advice)
Study: NCT03570580

Intervention type: OTHER
Intervention: OSA scoring
Description: OSA scoring (four scores: STOP-Bang, P-SAP, OSA50, DES-OSA were performed by several scorers on each patients, after what agreement between scores will be evaluated).
Study: NCT00822263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC)
Description: Anti-oxidant in a pill format

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control for study
Study: NCT02113969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Pessary
Description: Pessary fitting session at recruitment, follow up at 1 week, then monthly to complete 1 year follow up. QoL, symptoms and sexual function Surveys will be conducted at recruitment, 6 and 12 month. The absence of bacterial vaginosis (through study of vaginal discharge and pH) will be checked prior to positioning pessary and then each control. At the end of follow up period the success related variables will be determine with a statistical model. This information will be analyzed by an expert panel aiming to identify relevant clinical variables not included. This panel will generate a Standardized Management Protocol for symptomatic pelvic organ prolapse using vaginal pessaries.
Study: NCT04264559

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Infrared thermal imaging
Description: A thermal imager is used to record thermal images.The baseline temperature of relevant acupoints or sites on the Heart and Lung meridians will be measured.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Infrared thermal imaging
Description: A thermal imager is used to record thermal images.The baseline temperature of relevant acupoints or sites on the Heart and Lung meridians will be measured.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Infrared thermal imaging
Description: A thermal imager is used to record thermal images.The baseline temperature of relevant acupoints or sites on the Heart and Lung meridians will be measured.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively. During moxibustion, the temperature change of relevant acupoints or sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~* Intervention in the Heart meridian: moxibustion will be performed in acupoint HT3 of the Heart meridian for 15 minutes.~* Intervention in the Lung meridian: moxibustion will be performed in acupoint LU5 of the Lung meridian for 15 minutes.
Study: NCT04494178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2.0g G-PUR®
Description: Oral administration (Intervention period I)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2.0g G-PUR®
Description: Oral administration (Intervention period II)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intervention period I

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intervention period II
Study: NCT01757366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginsenoside Rg3 plus First-line Chemotherapy
Description: Ginsenoside Rg3 20mg 2/day po,patients will receive Ginsenoside Rg3 until progression~XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: First-line Chemotherapy
Description: XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
Study: NCT00642031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triciribine
Description: 15 mg/m\^2 IV Weekly Over 1 Hour On Days 1, 8, and 15.
Study: NCT03712137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOLUX XC
Description: Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with optional touch-up at day 30 and optional maintenance treatment at Month 12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-treatment control
Description: No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) at the beginning of the Post-Control period.
Study: NCT04384926

Intervention type: PROCEDURE
Intervention: Elective Cancer Surgery
Description: Planned, curative cancer surgery

Intervention type: PROCEDURE
Intervention: Elective Cancer Surgery
Description: Planned, curative cancer surgery
Study: NCT00490737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Description: 6mg/kg, i.v. infusion over 30 minutes; every 48 hours for a total of 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Description: 6mg/kg, i.v. infusion over 30 minutes; every 48 hours for a total of 3 doses